Body weight, cumulative feed intake, and survival were recorded while feed conversion ratio was calculated at week 8, 12, 16 and 20 during the growing period on-station.
Relationship between absorbed dose D corrected by the HEF and the tumor cell survival fraction (left axis) and metabolic ratio (right axis) calculated at week 7 post-therapy using the doubling time obtained by the global fit.
The model did not predict as well which districts would become affected during period 2. Of 167 districts in the countries bordering the primarily affected countries, the predicted probability of becoming affected was >20% for 9 districts (calculated at week 42).
Ingestion rate, gravimetric absorption, and assimilation efficiency of urchins fed the various diets were calculated at weeks 6 and 12.
For comparison, exponential growth rate was also calculated at weeks one through six.
Overall mean changes from baseline in DAS28 were calculated at weeks 52 and 104 for the analysis population by treatment group.
The percentage of patients achieving the threshold for at least one, two, or three PASS criteria (OA pain, patient's global assessment of disease activity, or WOMAC™ LK 3.1 Function subscale score) was calculated at weeks 2 and 13.
For both BASDAI and spine pain, the number and percentage of patients achieving ≥15%, ≥30 %, ≥50, and ≥70% improvement from bandline were calculated at Weeks 2, 4, and 6 and these values were used to determine the corresponding NNTs.
A biopsy of a psoriatic plaque, multiple arthroscopic synovial biopsies and a MRI scan of an inflamed knee joint were performed at baseline and week 12. HAQ scores, patient assessment of disease activity and pain using visual analogue scales were obtained at weeks 0 and 12. PsA-QoL were calculated at weeks 0 and 12.
The Sm-EDTMP uptake ratios of metastases/normal bone, kidneys/normal bone and liver/normal bone were calculated at baseline (week 1), week 3 and week 15.
Genotypic and phenotypic susceptibility scores were calculated at baseline (week 0) and week 2. Virus from 500 1,400 µL of plasma was pelleted by centrifugation (17,000×g, 1 hr, 4°C), resuspended in 140 µL of plasma, and extracted using the QIAamp viral RNA mini kit according to the manufacturer's instructions (Qiagen, Valencia, CA; see Supplementary Methods S1 for sample-specific plasma volumes).
